New Wave Esports – Ticker CSE – NWES
New Wave Esports is the first listed E-sports focused investment vehicle on the CSE, focused in sourcing the best investments opportunities in the competitive gaming growing industry, leveraging more than 50 years added in capital markets and gaming experience provided by the resourceful team behind this venture.
With 5 investments already in different verticals of business within the E-sports space. Seeking to help companies and developing projects to position themselves in the on-going market trend, giving investors the opportunity to allocate capital in diversified companies within the sector through a investors oriented firm.
Privately held gold mine on the outsides of Medellin, Colombia, One of the hottest
mining hubs in the region. 100% owners of the Guamo project with a production
capacity of more than 50 tons/day and the options to expands to several other
properties where minor discoverys have took place.
Being lead by a team of Canadian
Capital markets experts with an added experience of more than 70 years in the industry.
Planned to be listed in 2020.
A privately held e-commerce/Fintech company , Colombia based, with more
than 200,000 Downloads since launched in November 2018.
Planned to be listed by Q3 2020. Developing a keyboard embedded technology that allows
“Social Sellers”( Sellers who operate throughout messaging social platforms
such as Instagram, Facebook, Snapchat, Among others ) to manage their
inventories , CRM, Payment getaway, Catalog Management and therefore accelerating the selling process through Chat, for a better client service and
closing the “Last Mile of Sales”.
Khiron Life Sciences – TSX.V – KHRN
Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis.
With a focused regional strategy and patient oriented approach, the company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people.